AIM: To investigate -765G > C COX-2 polymorphism and H pylori infection in patients with gastric adenocarcinoma, peptic ulcer disease (PUD) and non-ulcer dyspepsia (NUD). METHODS: We enrolled 348 adult patients (62 gastric adenocarcinoma, 45 PUD and 241 NUD) undergoing upper gastrointestinal endoscopy at two referral centers between September, 2002 and May, 2007. H pylori infection was diagnosed when any of the four tests (RUT, culture, histopathology and PCR) were positive. Genotyping for -765G > C polymorphism of COX-2 was performed by PCR-RFLP analysis. RESULTS: Frequency of C carrier had significant association with gastric adenocarcinoma as compared to NUD [77.4% vs 29%, P < 0.001, odds ratio (OR) 8.20; 95% confidence interval (95% CI), 4.08-16.47] and PUD (77.4% vs 31.1%, P < 0.001; OR 8.04; 95% CI, 3.25-19.90). Risk of gastric adenocarcinoma was significantly higher in patients having C carrier with (OR 7.83; 95% CI 3.09-19.85) and without H pylori infection (OR 7.06; 95% CI, 2.61-19.09). Patients with C carrier and H pylori infection had significant risk for the development of PUD (P < 0.001; OR 5.65; 95% CI, 2.07-15.34). CONCLUSION: -765G > C COX-2 polymorphism with or without H pylori could be a marker for genetic susceptibility to gastric adenocarcinoma. COX-2 polymorphism in presence of H pylori infection might be useful in predicting the risk of PUD.
AIM: To investigate -765G > C COX-2 polymorphism and H pylori infection in patients with gastric adenocarcinoma, peptic ulcer disease (PUD) and non-ulcer dyspepsia (NUD). METHODS: We enrolled 348 adult patients (62 gastric adenocarcinoma, 45 PUD and 241 NUD) undergoing upper gastrointestinal endoscopy at two referral centers between September, 2002 and May, 2007. H pylori infection was diagnosed when any of the four tests (RUT, culture, histopathology and PCR) were positive. Genotyping for -765G > C polymorphism of COX-2 was performed by PCR-RFLP analysis. RESULTS: Frequency of C carrier had significant association with gastric adenocarcinoma as compared to NUD [77.4% vs 29%, P < 0.001, odds ratio (OR) 8.20; 95% confidence interval (95% CI), 4.08-16.47] and PUD (77.4% vs 31.1%, P < 0.001; OR 8.04; 95% CI, 3.25-19.90). Risk of gastric adenocarcinoma was significantly higher in patients having C carrier with (OR 7.83; 95% CI 3.09-19.85) and without H pylori infection (OR 7.06; 95% CI, 2.61-19.09). Patients with C carrier and H pylori infection had significant risk for the development of PUD (P < 0.001; OR 5.65; 95% CI, 2.07-15.34). CONCLUSION: -765G > C COX-2 polymorphism with or without H pylori could be a marker for genetic susceptibility to gastric adenocarcinoma. COX-2 polymorphism in presence of H pylori infection might be useful in predicting the risk of PUD.
Authors: Julie E Goodman; Elise D Bowman; Stephen J Chanock; Anthony J Alberg; Curtis C Harris Journal: Carcinogenesis Date: 2004-08-12 Impact factor: 4.944
Authors: Juliët H Hoff; Rene H M te Morsche; Hennie M J Roelofs; Elise M J van der Logt; Fokko M Nagengast; Wilbert H M Peters Journal: World J Gastroenterol Date: 2009-09-28 Impact factor: 5.742
Authors: María Asunción García-González; David Nicolás-Pérez; Angel Lanas; Luis Bujanda; Patricia Carrera; Rafael Benito; Mark Strunk; Federico Sopeña; Santos Santolaria; Elena Piazuelo; Pilar Jiménez; Rafael Campo; Jesús Espinel; Marisa Manzano; Fernando Geijo; María Pellisé; Ferrán González-Huix; Jorge Espinós; Manuel Zaballa; Llúcia Titó; Luis Barranco; Roberto Pazo; Enrique Quintero Journal: PLoS One Date: 2012-09-28 Impact factor: 3.240
Authors: Woon Geon Shin; Ha Jung Kim; Sung Jin Cho; Hyoung Su Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Hak Yang Kim Journal: Gut Liver Date: 2012-05-22 Impact factor: 4.519